Becker's Healthcare May 16, 2024
The FDA has granted accelerated approval to Bristol Myers Squibb’s Breyanzi, a CAR T-cell therapy indicated for types of lymphoma and leukemia.
Breyanzi (lisocabtagene maraleucel) is now approved for adults with relapsed or refractory follicular lymphoma who have received at least two other systemic therapies, according to a May 15 news...